MedTrace

Executive Summary

MedTrace Pharma is a Danish medical technology company pioneering an integrated hardware and software platform to enable point-of-care ¹⁵O-water PET imaging for absolute myocardial blood flow quantification. This gold-standard perfusion tracer has long been limited to research settings due to the complexity and cost of on-site radioisotope production. MedTrace’s solution addresses this bottleneck by miniaturizing and streamlining the production and delivery of ¹⁵O-water directly adjacent to a PET scanner, potentially transforming the diagnosis of coronary artery disease and other cardiovascular conditions. The platform is currently in Phase 3 clinical development and remains investigational. If successful, MedTrace could offer a more accurate, faster, and safer diagnostic alternative to current nuclear imaging methods, with the potential to reduce unnecessary invasive procedures. The company operates out of Copenhagen and is privately held, with no disclosed funding rounds or valuation. Given its advanced stage and the sizable addressable market in cardiovascular diagnostics, MedTrace represents a high-risk but high-reward opportunity contingent on successful clinical and regulatory outcomes.

Upcoming Catalysts (preview)

• Q4 2026Phase 3 Clinical Trial Readout60% success
• Q2 2027Regulatory Submission (CE Mark or FDA 510(k))50% success
• Q4 2026Strategic Partnership or Licensing Deal for Commercialization40% success